<DOC>
	<DOCNO>NCT01042366</DOCNO>
	<brief_summary>The purpose study determine effect use experimental tumor vaccine ( substance group substances mean cause immune system respond tumor ) make use patient ' tumor cell blood cell melanoma .</brief_summary>
	<brief_title>Dendritic Cells ( DC ) Vaccine Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Subjects must Stage IIIIV melanoma ( tumor thickness number lymph node involvement , intransit metastasis , distant metastasis ) ( AJCC ) . Each diagnosis confirm pathology review Melanoma Center University Pittsburgh Cancer Institute . All subject HLAA2 positive ( require immunologic test ) . Subjects must recover fully surgery . Availability resectable tissue bank tumor cell autologous tumor dendritic cell vaccine preparation . Sufficient number tumor cell available autologous tumor dendritic cell vaccine preparation ( min 2.6 x 10 7 ) . Sufficient number DCs least 12 X 10 6 preparation autologous tumor dendritic cell vaccine preparation ( less need number cell obtain one course leukopheresis , second leukopheresis repeat 2 week apart ) . Subjects must receive chemotherapy immunotherapy within four week precede vaccination ( six week nitrosourea , mitomycin ) . Subjects must expect survival great equal 12 month . Subjects must ECOG performance status 0 1 . Subjects must follow initial subsequent pretreatment laboratory parameter : Granulocytes &gt; =2,500/mm3 Lymphocytes &gt; =1000/mm3 Platelets &gt; 100,000/mm3 Serum Creatinine &lt; =1.5 X ULN AST , ALT , GGT , LDH , Alk phos &lt; = 2.5 X ULN Serum Bilirubin &lt; =1.5 X ULN Subjects must &gt; = 18 year age must able understand write informed consent . No evidence active infection , regardless degree severity localization . Subjects active infection ( whether require antibiotic therapy ) may eligible complete resolution infection . Subjects antibiotic therapy must antibiotics least 7 day begin treatment . Subjects measurable disease must evaluation extent disease ( tumor stag ) perform within 30 day start treatment . Pretreatment baseline evaluation laboratory parameter must obtain within 10 to18 day subject registration Subjects currently treat anti inflammatory agent include glucocorticoid therapy ineligible . Subjects currently treatment steroid ineligible , may receive DC autologous tumor dendritic cell vaccine 4 week steroid cessation . Subjects maintenance steroid adrenal insufficiency eligible . Subjects severely abnormal liver function test [ AST ( SGOT ) , ALT ( SGPT ) , GGT , Alk.Phos , LDH , total bilirubin great 2 X ULN ] . Subjects uncontrolled pain . Subjects autoimmune disease , HIV , hepatitis Subjects symptomatic brain metastasis . Subjects active prior malignancy ( exception nonmelanoma skin cancer carcinoma situ cervix ) . Subjects previously immunize melanoma vaccine 10 subject register treatment arm . Subjects pregnant . Subjects sensitivity drug provide local anesthesia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Melanoma</keyword>
</DOC>